Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.80
-0.1900-6.35%
Pre-market: 2.800.00000.00%08:16 EDT
Volume:1.03M
Turnover:2.96M
Market Cap:259.48M
PE:-19.37
High:2.97
Open:2.95
Low:2.78
Close:2.99
52wk High:10.40
52wk Low:2.26
Shares:92.67M
Float Shares:87.17M
Volume Ratio:0.91
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1446
EPS(LYR):-0.5438
ROE:-12.80%
ROA:-9.70%
PB:2.31
PE(LYR):-5.15

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

Anavex plans pivotal studies of blarcamesine targeting autism-Alzheimer’s shared autophagy dysfunction

Reuters
·
Apr 14

Anavex Life Sciences to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 07

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

BRIEF-Anavex Life Sciences Provides Comprehensive Regulatory Update

Reuters
·
Mar 30

Anavex keeps EMA talks after withdrawing EU blarcamesine filing for early Alzheimer’s

Reuters
·
Mar 30

Anavex Life Sciences Corp - Continues Dialogue With European Medicines Agency on Oral Blarcamesine for Early Alzheimer's Disease

THOMSON REUTERS
·
Mar 30

Ema's Chmp: Application for Initial Marketing Authorisation of Blarcamesine Anavex Was Withdrawn.

THOMSON REUTERS
·
Mar 27

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

Top Midday Decliners

MT Newswires Live
·
Mar 26

Anavex withdraws marketing authorization application for blarcamesine in the EU

TIPRANKS
·
Mar 25

Anavex Life Sciences Corp - Withdraws EU Marketing Authorization Application for Blarcamesine

THOMSON REUTERS
·
Mar 25

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

GlobeNewswire
·
Mar 25

Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion

Reuters
·
Mar 25

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 23

Anavex Life Sciences Presents New Data From Its Ad-004 Phase Iib/Iii Trial at Ad/Pd 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

THOMSON REUTERS
·
Mar 23

Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment

Reuters
·
Mar 23

Anavex reports blarcamesine motor function rescue in new Parkinson’s disease model at AD/PD 2026

Reuters
·
Mar 17

What's Going On With Anavex Life Sciences Stock On Wednesday?

Benzinga_recent_news
·
Mar 05

Anavex Life Sciences CEO Christopher Missling to Present at Citizens Life Sciences Conference

Reuters
·
Mar 03